Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2004

View Archived Issues

Kyowa Hakko presents anti-hIGF antibodies and their therapeutic use

French scientists describe new potentiators of antiplasmodial and antitumor agents

Novel chemopreventive and chemotherapeutic agents identified at the U. of Mississippi

Novel melanocortin receptor ligands discovered by Neurocrine researchers

New macrocyclic anti-HIV agents in early development at AIDS Care Pharma

Aphton commences Australian regulatory filing for G17DT

Xechem completes acquisition of Ceptor

CE Mark for Liberte

SEC clearance for Genome Therapeutics/Genesoft joint proxy statement

InSite Vision completes sale of ISV-403 to Bausch & Lomb

A year of milestones for Humira

Atrisone completes pivotal phase III acne studies

FDA clears Triage BNP Test for Beckman Coulter Immunoassay Systems

FDA marketing clearance for ChromaVision ACIS system

ISIS-104838 gives statistically significant disease response in phase II RA study

Japanese launch for Reyataz

Phase III trial of RG-1068 in autism fails to meet primary endpoints

Roche and Trimeris to develop next generation of HIV fusion inhibitors

Beneficial effects of tacrolimus in patients with refractory IBD

Clinical evidence of the efficacy of mitoxantrone in multiple sclerosis

Interferon alfacon-1 improves the clinical course of patients with SARS

Lower risk of transmission of genital herpes found with valaciclovir in heterosexual couples

AMD-3100 induces the mobilization of hematopoietic progenitor cells in healthy volunteers

Effective reduction of drooling found with BTX-A in patients with neurodegenerative disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...